Approach to patients with hypertriglyceridemia

Alan Chait; Kenneth R Feingold

doi:10.1016/j.beem.2022.101659

Approach to patients with hypertriglyceridemia

Best Pract Res Clin Endocrinol Metab. 2023 May;37(3):101659. doi: 10.1016/j.beem.2022.101659. Epub 2022 Apr 11.

Authors

Alan Chait¹, Kenneth R Feingold²

Affiliations

¹ Department of Medicine, Division of Metabolism, Endocrinology and Nutrition, University of Washington, Seattle, WA, USA. Electronic address: achait@uw.edu.
² University of California San Francisco, San Francisco, CA, USA. Electronic address: Kenneth.feingold@ucsf.edu.

PMID: 35459627
DOI: 10.1016/j.beem.2022.101659

Abstract

Elevated triglyceride levels increase the risk of arteriosclerotic cardiovascular disease (ASCVD) and severely elevated triglyceride levels also increase the risk of triglyceride-induced pancreatitis. Although substantially reducing triglyceride levels will prevent pancreatitis, whether lowering triglycerides per se will reduce CVD risk is unclear. In this review, we outline several principles that will help in deciding who and how to treat patients with elevated triglyceride levels in order to prevent both ASCVD and pancreatitis. Using these principles will help in making decisions regarding the treatment of elevated triglyceride levels.

Keywords: arteriosclerotic cardiovascular disease; chylomicrons; pancreatitis; very low-density lipoproteins.

Publication types

Review

MeSH terms

Humans
Hypertriglyceridemia* / complications
Hypertriglyceridemia* / drug therapy
Pancreatitis* / etiology
Pancreatitis* / prevention & control
Triglycerides

Substances

Triglycerides